Multiple preclinical studies have suggested that the immunomodulatory effects of CDK4/6 inhibitors may enhance the efficacy of ICIs, thereby providing a rationale for combination therapies in cancer patients [124, 148]. This evidence concerns the gene CDK4 and cancer.